Bullish Case: MMS rallied ~19% in a month to $63.68 off the $53 lows, and the Helium-market IV gap (about -2.3 across low strikes) shows market fear exceeding Helium's model — downside wings look overpriced. The historical return surface still concentrates likelihood near small gains, mid-strike call IVs (35-45%) are moderate, and a completed Q3 reset plus mean-reversion history could carry a retest of $68-72.

Bearish Case: The term structure remains backwardated and Helium's own price forecast is -2.45% with a historically ~zero/negative realized correlation, undercutting model conviction. The stock is still -23% year-over-year with a structurally impaired multiple; the market PDF carries heavy mass below $60 and deep short-dated puts quote extreme IVs (97-197%), signaling discontinuous downside risk if contract or federal-spending news sours.

Potential Outcomes:

1. 38% — Range $60-$67 through year-end; consistent with market PDF peak at $60-65 and post-rally consolidation. Falsifiable if 65P IV stays bid while $65 rejects.
2. 24% — Continuation rally to $68-$74; needs IV crush and federal-health contract flow; falsifiable on $67 reclaim with falling 55-60P IV.
3. 22% — Fade to $55-$60; backwardation and Helium's -2.45% forecast support a stall; falsifiable if $65 holds two weeks with flat IV.
4. 11% — Drop below $55 on adverse government-contract or budget news; deep-put wings realize.
5. 5% — Idiosyncratic IV spike/takeover interest; 20-40% realized vol with doubling short-dated IVs.

October 31, 2026